Literature DB >> 15123710

Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase.

Clifford D Mol1, Douglas R Dougan, Thomas R Schneider, Robert J Skene, Michelle L Kraus, Daniel N Scheibe, Gyorgy P Snell, Hua Zou, Bi-Ching Sang, Keith P Wilson.   

Abstract

The activity of the c-Kit receptor protein-tyrosine kinase is tightly regulated in normal cells, whereas deregulated c-Kit kinase activity is implicated in the pathogenesis of human cancers. The c-Kit juxtamembrane region is known to have an autoinhibitory function; however the precise mechanism by which c-Kit is maintained in an autoinhibited state is not known. We report the 1.9-A resolution crystal structure of native c-Kit kinase in an autoinhibited conformation and compare it with active c-Kit kinase. Autoinhibited c-Kit is stabilized by the juxtamembrane domain, which inserts into the kinase-active site and disrupts formation of the activated structure. A 1.6-A crystal structure of c-Kit in complex with STI-571 (Imatinib or Gleevec) demonstrates that inhibitor binding disrupts this natural mechanism for maintaining c-Kit in an autoinhibited state. Together, these results provide a structural basis for understanding c-Kit kinase autoinhibition and will facilitate the structure-guided design of specific inhibitors that target the activated and autoinhibited conformations of c-Kit kinase.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15123710     DOI: 10.1074/jbc.M403319200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  175 in total

1.  Binding free energy calculation with QM/MM hybrid methods for Abl-Kinase inhibitor.

Authors:  Kshatresh Dutta Dubey; Rajendra Prasad Ojha
Journal:  J Biol Phys       Date:  2010-09-02       Impact factor: 1.365

2.  Structural basis for c-KIT inhibition by the suppressor of cytokine signaling 6 (SOCS6) ubiquitin ligase.

Authors:  Fahad Zadjali; Ashley C W Pike; Mattias Vesterlund; Jianmin Sun; Chenggang Wu; Shawn S C Li; Lars Rönnstrand; Stefan Knapp; Alex N Bullock; Amilcar Flores-Morales
Journal:  J Biol Chem       Date:  2010-10-28       Impact factor: 5.157

3.  Incomplete protein packing as a selectivity filter in drug design.

Authors:  Ariel Fernández
Journal:  Structure       Date:  2005-12       Impact factor: 5.006

4.  Packing defects as selectivity switches for drug-based protein inhibitors.

Authors:  Ariel Fernández; Ridgway Scott; R Stephen Berry
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-30       Impact factor: 11.205

5.  Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK.

Authors:  Anna V Galkin; Jonathan S Melnick; Sungjoon Kim; Tami L Hood; Nanxin Li; Lintong Li; Gang Xia; Ruo Steensma; Greg Chopiuk; Jiqing Jiang; Yongqin Wan; Peter Ding; Yi Liu; Fangxian Sun; Peter G Schultz; Nathanael S Gray; Markus Warmuth
Journal:  Proc Natl Acad Sci U S A       Date:  2006-12-21       Impact factor: 11.205

6.  Feature-similarity protein classifier as a ligand engineering tool.

Authors:  Sridhar Maddipati; Ariel Fernández
Journal:  Biomol Eng       Date:  2006-10-10

Review 7.  Receptor tyrosine kinases: mechanisms of activation and signaling.

Authors:  Stevan R Hubbard; W Todd Miller
Journal:  Curr Opin Cell Biol       Date:  2007-02-16       Impact factor: 8.382

8.  Anti-KIT monoclonal antibody inhibits imatinib-resistant gastrointestinal stromal tumor growth.

Authors:  Badreddin Edris; Stephen B Willingham; Kipp Weiskopf; Anne K Volkmer; Jens-Peter Volkmer; Thomas Mühlenberg; Kelli D Montgomery; Humberto Contreras-Trujillo; Agnieszka Czechowicz; Jonathan A Fletcher; Robert B West; Irving L Weissman; Matt van de Rijn
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-04       Impact factor: 11.205

9.  Molecular characterisation of gastrointestinal stromal tumours in a South African population.

Authors:  Gillian Baker; Chantal Babb; Desmond Schnugh; Simon Nayler; Melanie Louw; Jacqueline Goedhals; Pierre-Paul Bringuier; Jean-Yves Blay; Pascale Willem
Journal:  Oncol Lett       Date:  2012-11-05       Impact factor: 2.967

10.  miR-155 drives oncogenesis by promoting and cooperating with mutations in the c-Kit oncogene.

Authors:  Lisa W Witten; Christopher J Cheng; Frank J Slack
Journal:  Oncogene       Date:  2018-11-20       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.